| 摘要 |
This invention concerns the use of a compound of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is halo; C<SUB>1-6</SUB>alkyl; C<SUB>1-6</SUB>alkyl substituted with hydroxy, carboxyl, cyano, amino, mono- or di(C<SUB>1-6</SUB>alkyl)amino, aminocarbonyl, mono- or di(C<SUB>1-6</SUB>alkyl)aminocarbonyl, C<SUB>1-6</SUB>alkyloxycarbonyl or C<SUB>1-6</SUB>alkyloxy; polyhaloC<SUB>1-4</SUB>alkyl; C<SUB>1-4</SUB>alkyloxy; cyano; amino; aminocarbonyl; mono- or di(C<SUB>1-6</SUB>alkyl)aminocarbonyl; C<SUB>1-6</SUB>alkyloxycarbonyl; C<SUB>1-6</SUB>alkylcarbonyloxy; H<SUB>2</SUB>N-S(-O)<SUB>2</SUB>-; mono- or di(C<SUB>1-6</SUB>alkyl)amino-S(-O)<SUB>2</SUB>; -C(-N-R<SUP>x</SUP>)NR<SUP>y</SUP>R<SUP>z</SUP>; Q is an optionally substituted carbocycle or an optionally substituted heterocycle; L is substituted phenyl or an optionally substituted monocyclic 5 or 6-membered partially saturated or aromatic heterocycle or a bicyclic partially saturated or aromatic heterocycle; aryl is optionally substituted phenyl; for the manufacture of a medicament for the prevention or the treatment of diseases mediated through TNF-alpha and/or IL-12. |
